ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EYPT
PRPO (30) RPID (34) HBIO (47) BNGO (29) ⌘ Pro Terminal →

EyePoint Inc. (EYPT) — RQD Stock Rating Cockpit

$0.37 +7.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.37

EyePoint Inc. (EYPT) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $30.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EYPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, EyePoint Inc. (NASDAQ: EYPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.37 (+7.58% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EYPT ranks #915 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EYPT compare to PRPO and RPID in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EYPT?
▼

Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.37 (+1.17%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$20 Bull$0 Base$0 Bear
📬 FREE EYPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EYPT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY EYPT SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$3.07-86.6% Next Q
Q2 (-2Q)
31
Grade E$0.41-12.2% Next Q
Q3 (-1Q)
29
Grade E$0.36+2.8% Next Q
Current
26
Grade E$0.37-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EYPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EYPT currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.02) and Max Pain ($0.39) forces dealer call-delta covering toward $20.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EYPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EYPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
16.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $0$0.37H: $19
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on EYPT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

6/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like EYPT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EYPT)

  • ✓Walkthrough of EYPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EYPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.33%▼ DESCENDING CHANNEL
2026-11-03O $0.38H $0.38L $0.35C $0.37VOL 6.12M
RES: $12.66SUP: $-2.77SMA50: $3.02SMA200: $10.83
$17.01$12.49$7.97$3.46$-1.06RES $12.66SUP $-2.77$0.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EYPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EYPT Butterfly Map → + Track EYPT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -27.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EYPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EYPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EYPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EYPT)

Health Care Rank #915 of 1015 ⚔️ PRPO vs EYPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EYPT vs. PRPO, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, EyePoint Inc. (EYPT) ranks #915 by composite RQD confidence (26/100, grade E) and #795 by equity capitalization ($30.0M). Within this direct 5-issuer industry benchmark cohort, EYPT leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EYPT at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EYPT ACTIVE
EyePoint Inc.
E 26/100 — — -35.0% +7.58% $30.0M Benchmark Subject
PRPO
Precipio Inc.
E 30/100 — 44.2% -7.9% -1.71% $32.4M /prpo-vs-eypt →
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 — — -35.0% -4.50% $36.9M /rpid-vs-eypt →
HBIO
Harvard Bioscience Inc.
D 47/100 — 57.7% -35.0% -3.37% $40.5M /hbio-vs-eypt →
BNGO
Bionano Genomics Inc.
E 29/100 — 46.3% -35.0% +0.87% $16.1M /bngo-vs-eypt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001314102 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EyePoint Inc. (EYPT) reported GAAP revenue of $31.4M (-27.5% vs. FY2024 revenue of $43.3M , and -31.8% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of -$240.1M, and free cash flow of -$243.4M (-86.8% YoY). On the balance sheet, EYPT closed FY2025 with $364.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $31.4M -$232.0M -$240.1M -$243.4M $364.0M —
FY2024 (FY) 2024-12-31 $43.3M -$130.9M -$126.2M -$130.3M $418.5M —
FY2023 (FY) 2023-12-31 $46.0M -$70.8M $1.9M $1.9M — —

3. EYPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, EyePoint Inc. (NASDAQ: EYPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.37 (+7.58% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EYPT ranks #915 in composite RQD confidence.

How does EYPT compare to PRPO and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EYPT?

Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EYPT trading relative to its 50-day, 200-day, and 52-week technical levels?

EYPT last traded at $0.37 (+7.58% on volume of 6,327,753 shares), positioning the stock -87.75% below its 50-day simple moving average ($3.02) and -96.58% below its 200-day simple moving average ($10.83). Across its 52-week range of $0.34 to $19.11, EYPT sits at the 0.2% percentile with a 14-day RSI of 16.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).

Direct Sub-Reports: EYPT RQD Cockpit EYPT 12M Forecast EYPT Earnings & Move EYPT Dividends & DRIP EYPT Insiders & 13F EYPT Whale Options EYPT Profit Sankey EYPT News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

EYPT — EyePoint Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

EyePoint Inc. (EYPT) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.37 (+7.58% 1D, market capitalization $30.0M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

EyePoint Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Laboratory Analytical Instruments, . Reported revenue declined from $46.0M (FY 2023) to $43.3M (FY 2024) to $31.4M (FY 2025).

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), EyePoint Inc. (EYPT) reported $31.4M in annual revenue (up from $43.3M in FY2024, -27.5% YoY) and -$232.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.0M revenue, -$70.8M net income) through FY2025, EYPT scaled operating cash flow to -$240.1M and free cash flow to -$243.4M, backed by $364.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.34 – $19.11 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), EYPT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can EYPT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $31.4M and free cash flow of -$243.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is EYPT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EYPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for EyePoint Inc. (EYPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EYPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EYPT Bull vs. Bear Conversation Board — What's Your Call at $0.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EYPT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EYPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.43 (+22.9%)
📌 Pinned Debate

The reported $101.8M of FY 2025 cash exceeds the $32.8M market capitalization.

Here is why I am bullish on EYPT here at $0.35: The reported $101.8M of FY 2025 cash exceeds the $32.8M market capitalization.. Compare EYPT's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $0.33 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — EYPT's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.27 (-22.9%)
Spot @ $0.35

FY 2025 free cash flow of -$243.4M and a 26 RQD score point to a severe forensic risk profile.

I respect the product at EyePoint Inc., but the stock at $0.35 is a different story. FY 2025 free cash flow of -$243.4M and a 26 RQD score point to a severe forensic risk profile.. FCF yield is 0.0% and RQD sits at 26/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE